Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study

Abstract

Our group recently showed that the (ASNase) formulation available in Bra-zil from 2017 to 2018 when used at the same dose and frequency as theformulation provided previously did not reach the activity considered ther-apeutic. Based on these, our goal was to assess the impact of these facts onthe prognosis of children with ALL at different oncology centers. A multi-centre retrospective observational study followed by a prospective follow-up. Patients aged>1 and<18 years in first-line treatment followed up at 10referral centres, between 2014 and 2018 who received the formulationLeuginaseâwere identified (Group B). For each patient, the centre regis-tered 2 patients who received ASNase in the presentation of Aginasaâexclusively (Group A). Data collection was registered using (Redcapâ). Atotal of 419 patients were included; 282 in Group A and 137 in B. GroupA had a 3-year OS and EFS of 91 8% and 84 8% respectively, while GroupB had a 3-year OS of 83 8% (P=0 003) and EFS of 76 1% (P=0 008).There was an impact on 3-year OS and EFS of children who received a for-mulation. This result highlights the importance of evaluating ASNase andmonitoring its activity.